Liposomal treatment of xerostomia, odor, and taste abnormalities in patients with head and neck cancer

Heiser, Clemens; Hofauer, Benedikt; Scherer, Elias Q.; Schukraft, Johannes; Knopf, Andreas

doi:10.1002/hed.24198

Cited by 18 publications

(12 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Different application forms (mouth spray, nose spray, eye spray) have been used to treat xerostomia, rhinitis sicca and keratoconjunctivitis sicca in 73 patients an significant improvement could be achieved [11]. Results from another trial in patients after treatment of head and neck cancer demonstrated that a liposomal spray could improve smell and taste disorders in addition to xerostomia [23].…”

Section: Discussionmentioning

confidence: 99%

Inhalative Treatment of Laryngitis Sicca in Patients with Sjögren’s Syndrome—A Pilot Study

Hofauer

Kirschstein

Graf

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

Xerostomia and keratoconjunctivitis sicca are the main symptoms of Sjögren’s syndrome. Often patients also suffer from laryngeal complaints, but there is a lack of specific treatment options. The aim of this study was to evaluate the effect of a liposomal inhalation therapy. Patients with Sjögren’s syndrome were included and received a two-month period of liposomal inhalation therapy. The effect was evaluated by standardized questionnaires (patient-reported indices) and measurement of unstimulated whole salivary flow and glandular stiffness. Forty-five patients were included in this study. A comparison of baseline and therapeutic values demonstrated a significant improvement of the EULAR Sjögren’s syndrome patient reported index (ESSPRI) with a baseline of 5.0 ± 2.1 and a therapeutic value of 4.1 ± 2.4 (p = 0.012). This improvement was mainly based on the item on dryness within this score. Overall, the therapy was well tolerated. In conclusion, an inhalative application of liposomes had a beneficial effect on the reported dryness in patients with Sjögren’s syndrome. A first insight into the effect of inhalation therapy on laryngeal symptoms could thus be obtained and at the same time the basis was created on which case calculations can be carried out in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

Inhalative Treatment of Laryngitis Sicca in Patients with Sjögren’s Syndrome—A Pilot Study

Hofauer

Kirschstein

Graf

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…They easily fuse with the cell membrane of the nasal mucosa to form a natural defense [12]. Phospholipid surfactants are bene cial for reducing the surface tension at the nasal air-mucus interface and lubricating the nasal cavity, increasing the ciliary beat frequency, reducing the adhesion of pathogenic microorganisms or allergens, stabilizing the barrier of the respiratory tract and enhancing the anti-in ammatory and wound-healing capacities of the upper airway mucosa, including the nasal mucosa [12][13][14][15][16][17].…”

Section: Potential Mechanisms Of Surfrin®mentioning

confidence: 99%

“…They make up most of the protective nasal surfactant layer [12,13]. Liposomes, which consist of phospholipids, can protect the nasal mucous membrane by complementing the lipid layer [14], removing antigens and improving mucociliary clearance by mechanical cleansing [13,15], and aid in healing the damaged nasal mucosa by covering the surface of the mucosa [13,16,17].…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Surfrin Intranasal Spray, a Natural Phospholipid Spray, in Treating Patients With Acute Rhinitis: a Multicenter, Randomized, Controlled Trial

Li¹,

Xia²,

Luo³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Phospholipids form a natural defense and self-cleansing system in the nose, and the phospholipids supplemented via nasal sprays might stabilize or restore the impaired “nasal surfactant,” thereby maintaining the natural moisture film, protecting and moisturizing the nasal mucosa, and facilitating mucociliary clearance. Acute rhinitis is a self-limited, prevalent human disease caused by viral infection of the upper respiratory tract and is characterized by nasal dryness, sneezing, nasal congestion and discharge. Acute rhinitis is currently treated by symptom alleviation. This study investigates the efficacy and safety of a natural phospholipid intranasal spray in attenuating the nasal discomfort of patients with acute rhinitis. Methods: In this randomized, positive control, noninferiority trial, 144 patients with acute rhinitis were recruited by otolaryngologists in two Grade 3A public and research hospitals, and randomly allocated to experimental and control groups in a 1:1 ratio to receive a natural phospholipid spray, i.e., Surfrin® Intranasal Spray (Surfrin®), or a physiological sea water nasal spray, i.e., Bright Nose® Physiological Sea Water Nasal Spray (BNNS), respectively. The primary outcome was the effective rate, which was judged by the nasal sign score reduction index. The secondary outcome was changes in the total scores of nasal symptoms (TNSS). Any adverse events (AEs) of the study were recorded.Results: In the final statistical analysis, there were 68 participants in the experimental group and 71 participants in the control group. The effective rates of Surfrin® and BNNS were 98.5% and 91.5%, respectively. The TNSS decreased from 5.75±1.83 to 0.96±1.35 in the experimental group, and from 5.65±1.48 to 1.20±1.38 in the control group. The experimental group had one AE not related to treatment (1.41%), and another occurred in the control group (1.39%) and was probably related to treatment. No serious AEs or adverse reactions occurred.Conclusions: The results of this trial demonstrate the good safety and efficacy of the natural phospholipid Surfrin® Intranasal Spray as an alternative treatment for acute rhinitis. Trial registration: Chinese Clinical Trial Registry, Identifier: ChiCTR1900025655, September 4, 2019, retrospectively registered).

show abstract

“…Therapeutics based on lecithin as principal component (e.g. nasal spray and inhalation solution) have been shown to be effective in the treatment of various health disorders, such as allergic rhinitis [ 43 ], rhinitis sicca [ 45 , 47 ], sinunasal symptoms [ 48 ], and care after tracheostomy [ 49 ]. Chronic respiratory disease e.g.…”

Section: Introductionmentioning

confidence: 99%

Phospholipids dock SARS-CoV-2 spike protein via hydrophobic interactions: a minimal in-silico study of lecithin nasal spray therapy

et al. 2021

View full text Add to dashboard Cite

Liposomal treatment of xerostomia, odor, and taste abnormalities in patients with head and neck cancer

Abstract: Our results demonstrate that using nonpharmaceutical liposomal sprays improve smell, taste, and symptoms of xerostomia in patients with head and neck cancer. © 2015 Wiley Periodicals, Inc. Head Neck 38: E1232-E1237, 2016.

Cited by 18 publications

References 35 publications

Inhalative Treatment of Laryngitis Sicca in Patients with Sjögren’s Syndrome—A Pilot Study

Inhalative Treatment of Laryngitis Sicca in Patients with Sjögren’s Syndrome—A Pilot Study

Efficacy and Safety of Surfrin Intranasal Spray, a Natural Phospholipid Spray, in Treating Patients With Acute Rhinitis: a Multicenter, Randomized, Controlled Trial

Phospholipids dock SARS-CoV-2 spike protein via hydrophobic interactions: a minimal in-silico study of lecithin nasal spray therapy

Contact Info

Product

Resources

About